Bill > HB05485

This bill establishes a state-run captive insurance company with $10 million in state funding for the fiscal year ending June 30, 2026, specifically designed to help individuals access glucagon-like peptide-1 (GLP-1) prescription drugs for obesity treatment. GLP-1 receptor antagonist drugs, such as Ozempic and Wegovy, are medications that help manage weight and metabolic conditions. The captive insurance company will perform two primary functions: first, it will bulk purchase these prescription drugs directly from drug manufacturers at potentially lower prices, and second, it will distribute these medications to qualifying state residents who cannot obtain the drugs through their current health insurance. To receive these medications, individuals must pass a means-tested qualification process that demonstrates their financial need and inability to access the drugs through their existing health insurance. This approach aims to improve access to obesity treatment medications for residents who might otherwise be unable to afford or obtain these potentially costly prescription drugs.

Business and Industry

https://www.cga.ct.gov/asp/cgabillstatus/cgabillstatus.asp?selBillType=Bill&bill_num=HB05485&which_year=2025